FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis

Figure 1 Flow diagram of patient selection process. NAFLD: Non-alcoholic fatty liver disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; LSM: Liver stiffness measurement; CAP: Controlled attenuation parameter; MASH: Metabolic dysfunction-associated steatohepatitis; NAS: Non-alcoholic fatty liver disease activity score.